AlphaQuest LLC Sells 350 Shares of Insulet Corporation $PODD

AlphaQuest LLC cut its position in shares of Insulet Corporation (NASDAQ:PODD) by 22.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,240 shares of the medical instruments supplier’s stock after selling 350 shares during the period. AlphaQuest LLC’s holdings in Insulet were worth $390,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC raised its position in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in Insulet during the first quarter worth $26,000. SouthState Corp lifted its holdings in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the period. Kozak & Associates Inc. purchased a new stake in Insulet during the second quarter worth $32,000. Finally, Trust Co. of Toledo NA OH purchased a new stake in Insulet during the second quarter worth $35,000.

Insulet Stock Performance

Shares of PODD stock opened at $316.17 on Thursday. The business’s fifty day simple moving average is $327.26 and its 200-day simple moving average is $306.48. The company has a market cap of $22.26 billion, a PE ratio of 96.10, a PEG ratio of 2.71 and a beta of 1.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $227.03 and a 12-month high of $353.50.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PODD shares. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Morgan Stanley restated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Stifel Nicolaus started coverage on Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price for the company. The Goldman Sachs Group lowered their target price on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Finally, Citigroup restated a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $352.11.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.